Skip to Main Content


  • Define modified-release drug products.

  • Differentiate between conventional, immediate-release, extended-release, delayed-release, and targeted drug products.

  • Explain the advantages and disadvantages of extended-release drug products.

  • Describe the kinetics of extended-release drug products compared to immediate-release drug products.

  • Explain when an extended-release drug product should contain an immediate-release drug dose.

  • Explain why extended-release beads in capsule formulation may have a different bioavailability profile compared to an extended-release tablet formulation of the same drug.

  • Describe several approaches for the formulation of an oral extended-release drug product.

  • Explain why a transdermal drug product (patch) may be considered an extended-release drug product.

  • Describe the components of a transdermal drug delivery system.

  • Explain why an extended-release formulation of a drug may have a different efficacy profile compared to the same dose of drug given in as a conventional, immediate-release, oral dosage form in multiple doses.

  • List the studies that might be required for the development of an extended-release drug product.

  • List the several achievements on the drug devices based on the modified-release drug design.


Most conventional (also named as immediate-release, IR) oral drug products, such as tablets and capsules, are formulated to release the active pharmaceutical ingredient (API) immediately after oral administration. In the formulation of conventional drug products, no deliberate effort is made to modify the drug release rate. Usually, immediate-release products generally result in relatively rapid drug absorption and onset of accompanying pharmacodynamic (PD) effects, but not always. In the case of conventional oral products containing prodrugs, the pharmacodynamic activity may be altered due to the time consumption with conversion from prodrugs to the active drug by hepatic or intestinal metabolism or by chemical hydrolysis. Alternatively, in the case of conventional oral products containing poorly soluble (lipophilic drugs), drug absorption may be gradual due to slow dissolution in or selective absorption across the GI tract, also resulting in a delayed onset time.

In order to achieve a desired therapeutic objective or better patient compliance, the pattern of drug release from modified-release (MR) dosage forms is deliberately changed from that of a conventional (immediate-release, IR) dosage formulation. MR drug products have always been more effective therapeutic alternative to conventional or IR dosage forms. The objective of MR drug products for oral administration is to control the release of the therapeutic agent and thus control drug absorption from gastrointestinal tract. Types of MR drug products include, but not limited to, delayed-release (eg, enteric-coated), extended-release (ER), and orally disintegrating tablets (ODT).

The term modified-release (MR) drug product is used to describe products that alter the timing and/or rate of release of the drug substance in the formulation. A modified-release dosage form is a formulation in which the drug-release characteristics of time course and/or location are chosen to accomplish therapeutic or convenience objectives, which is not offered by conventional dosage forms such as solutions, ointments, ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.